ArticleBMC research notes2025
Sodium alginate-hyaluronic acid composite particles for doxorubicin delivery: in vitro characterization and cytotoxicity evaluation.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gel Microspheres as Multifunctional Carriers for Photodynamic Therapy: Advancing Hepatocellular Carcinoma Treatment.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to develop sodium alginate-hyaluronic acid (SA-HA) composite microspheres for targeted doxorubicin (DOX) delivery in hepatocellular carcinoma (HCC) treatment. The research sought to address key limitations of current transcatheter arterial chemoembolization (TACE) agents by combining SA’s mechanical stability with HA’s tumor-targeting capability, while optimizing drug loading and release kinetics.
resultsThe SA-HA microspheres exhibited enhanced physicochemical properties, including 28.4% lower porosity (SEM) and 3.6-fold higher swelling capacity (5.42% at 6 h) compared to SA controls. FTIR confirmed successful ionic crosslinking, while drug loading efficiency reached 89.2% - significantly higher than conventional SA systems. In vitro release studies demonstrated sustained DOX release (85.2 ± 3.1% at 24 h, first-order kinetics R² = 0.95), with superior cytotoxicity against HepG2 cells (IC50 = 0.48 ± 0.03 µg/mL vs. free DOX 1.12 ± 0.05 µg/mL, p < 0.05). These results validate SA-HA microspheres as a promising TACE-compatible platform for HCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.